EU Approves Sanofi Commitments, Closing Flu Vaccine Marketing Probe

what happened

The European Union's antitrust body has accepted concessions from French drugmaker Sanofi, ending its competition investigation into a flu vaccine marketing campaign. According to The Wall Street Journal, the company offered to correct the possible effects of its earlier messages about a rival flu shot, Fluad, made by Australia's CSL. The Commission said these commitments will become legally binding for Sanofi.

Sanofi said it cooperated with regulators throughout the inquiry, which ended without any finding of infringement. Under the commitments, for two years Sanofi will post a clarification on its German and French websites and send it to German healthcare professionals it had previously targeted. Until 2030 the company will also refrain from any communication that casts doubt on Fluad's performance. CSL Seqirus said the decision supports fair competition and accurate vaccine communications based on independent scientific assessments and national recommendations.

why it matters

For markets, the case closes without a finding of infringement, yet Sanofi's promotion of its Efluelda vaccine in France and Germany will now be limited by binding commitments across several flu seasons. The outcome shows how EU enforcers scrutinise comparative claims by drugmakers about competitors, which matters for CSL as the maker of Fluad. The source does not mention any financial penalty.

tags

instruments